SUPPLEMENTAL MATERIALS
|
|
- Noah Alexander
- 5 years ago
- Views:
Transcription
1 SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table S3: IRRs for CO1 (efficacy) and CO2 (safety) for the comparison of event rates in PSM-matched patients who received specific NOAC agents versus VKA patients Table S4: PSM-adjusted IRRs in the two sensitivity analyses considering (a) therapy-naïve patients (Cohort 1a / 2a) and (b) end of follow up if a 30 days gap was observed (Cohort 1 / 2) Figure S1a: Results of the multivariable Cox Regression analysis addressing composite outcome 3, based on Cohorts 1 and 2 Figure S1b: Results of the multivariable Cox Regression analysis addressing composite outcome 1 (effectiveness), based on Cohorts 1 and 2 Figure S1c: Results of the multivariable Cox Regression analysis addressing composite outcome 2 (safety), based on Cohorts 1 and 2 1
2 Table S1: Variables included in the propensity-score matching. The table outlines the definition of all 32 variables used for the PSM analysis that led to the PSM cohort. A backward elimination logistic regression using group exposition as dependent variable was applied. Please note that all independent variables included in the logistic regression estimates were based on the 12 months before index date. Variable Description Age per index year Gender CHA2DS2Vasc score CCI Highest level of nursing care: 0-4 (reference=0) Nb. of prescribed long-term medication Nb. of physician visits Prescription of antihypertensive agents Prescription of oral antidiabetic agents Prescription of insulin Prescription of antiarrhythmic agents Prescription of NSAIDs Prescription of antiplatelets Prescription of lipid lowering agents Prescription of antiulcerants Prescription of cardiac glycosides Prescription of oral corticosteroids Prescription of benzodiazepines Acute hosp. with ischaemic stroke Acute hosp. with haemorrhagic stroke Acute hosp. with non-specific stroke Acute hosp. with arterial embolism Acute hosp. with TIA Acute hosp. with myocardial infarction Acute hosp. with severe bleeding Acute hosp. due to other heart diseases (years) (male/female) Score (see description in table S1.1) Charlson Comorbidity Index (CCI) score Level of nursing care as documented in the database Number of prescribed medications (only those agents that had been prescribed at least twice in the 12 months baseline period, excluding VKAs, NOACs and antibiotics) Number of visits (yes/no; ATC: C02* and C06A*) (yes/no; ATC: A10B* and A10X*) (yes/no; ATC: A10A*) (yes/no; ATC: C08* and C01B* and C07AB* and C07AG*) Nonsteroidal anti-inflammatory drugs (yes/no; ATC: M01*) (yes/no; ATC: B01AC*) (yes/no; ATC: C10*) (yes/no; ATC: A02B*) (yes/no; ATC: C01A%) (yes/no; ATC: H02%) (yes/no; ATC: N05BA*) 2
3 Peripheral vascular disease Other cerebrovascular diseases Severe kidney disease/acute renal failure Mild to moderate kidney disease Dementia Alcohol abuse (yes/no; ICD-10 I70.-/I71.-/I72.-/I73.-) (yes/no; ICD-10 I65.-/I66.-/I67.-/I68.-/I69.-) (yes/no; at least one outpatient and/or inpatient diagnosis ICD-10 N17.-/ N18.4/N18.5) (yes/no; at least one outpatient and/or inpatient diagnosis ICD-10 N18.1-N18.3/N18.9/N19-) (yes/no; ICD-10 F00.-/F01.-/F02.-/F03.-) (yes/no; ICD-10 F10.-) Table S1.1: Components of the CHA2DS2Vasc score. The table contains the components of the calculated CHA2DS2Vasc score and describes the score methodology used based on observed outpatient/inpatient ICD-10 codes and sociodemographic information available in the database. All data was based on a 12 months baseline period before index date. Risk factor CHA 2DS 2- VASc-score value Used ICD-10 code (at least one documented outpatient or inpatient diagnosis) Heart failure 1 I50.- Hypertension 1 I10.- Age years 1 - Age 75 years 2 - Diabetes mellitus 1 E11.-/E10.-/E12.- Stroke/TIA/embolism 2 Vascular disease (prior myocardial infarction/ peripheral artery disease/aortic plaque) I61.-/I63.-/I64.-/I69.-/ I82.-/G45.-/I74.-/ K55.0/N28.0/H I21.-/I22.-/I23.-/I73.- Female gender 1 - ICD-10: 10th revision of the International Statistical Classification of Diseases and Related Health Problems; TIA:transient ischaemic attack 3
4 Table S2: Crude event rates in the compared AF patient cohorts Observed outcome Event frequencies: number of observed events per 100 patient years in the followup period Cohort 1 (NOAC) N = 51,155 patients Cohort 2 (VKA) N = 128,274 patients IRR (95% CI) Cohort 1 vs. 2 Time to first event during the follow-up period Unadjusted HR (95% CI) Cohort 1 vs. 2 a: Death ( )**** 1.88 ( )**** b: IS ( )**** 2.59 ( )**** c: Non-specified stroke ( )**** 2.85 ( )**** d: TIA ( )**** 2.16 ( )**** e: MI ( )**** 1.56 ( )**** f: AE ( )**** 2.41( )**** g: Haemorrhagic stroke ( )* 1.19 ( )* h: Severe bleedings ( )**** 2.36 ( )**** CO 1 (a-f) ( )**** 1.95 ( )**** CO 2 (g and h) ( )**** 2.08 ( )**** CO 3 (a-h) ( )**** 1.97 ( )**** * p < 0.050; ** p < 0.010; *** p < 0.005; ****p < AE: arterial embolism; CI: confidence interval 95%; CO1: effectiveness composite outcome 1; CO2: safety composite outcome 2; CO3: general composite outcome 3; HR: hazard ratio; IRR: incidence rate ratio; IS: ischaemic stroke; MI: myocardial infarction; NOAC: non-vitamin K antagonist oral anticoagulants; PSM: propensity score matched; TIA:transient ischaemic attack; VKA: vitamin-kantagonist Legend: The table lists results of the crude event rate analysis based on patient-specific follow-up periods. Results are reported as incidence rate ratios (IRRs) for events per 100 observed patient-years and unadjusted Hazard Ratios (HRs) for time to first event. 4
5 Table S3: IRRs for CO1 (efficacy) and CO2 (safety) for the comparison of event rates in PSM-matched patients who received specific NOAC agents versus VKA patients. The table shows the PSM-IRRs for Cohort 1 (NOAC) vs. Cohort 2 (VKA) separately for Dabigatran, Rivaroxaban and Apixaban. Events Dabigatran vs. VKA Rivaroxaban vs. VKA Apixaban vs. VKA CO ( )**** 1.38 ( )**** 1.30 ( )**** CO ( ) 1.92 ( )**** 1.23 ( ) Observed patients per group (Cohort 1/2) 9,832 25,269 2,338 Observed patient-years Cohort 1 (NOAC) 11,174 23,372 1,201 Observed patient-years Cohort 2 (VKA) * p < 0.050; ** p < 0.010; *** p < 0.005; ****p < ,983 25,338 2,167 CI: confidence interval 95%; %; CO1: effectiveness composite outcome 1; CO2: safety composite outcome 2; IRR: Incidence rate ratio; NOAC: non-vitamin K antagonist oral anticoagulants; PSM: Propensity score matching; VKA: vitamin-k-antagonist 5
6 Table S4: PSM-adjusted IRRs in the two sensitivity analyses considering (a) therapy-naïve patients (Cohort 1a / 2a) and (b) end of follow up if a 30 days gap was observed (Cohort 1 / 2) Events Therapy-naïve patients Considering periods without treatment gaps > 30 days Incidence rate per 100 patient-years in Cohort 1a (NOAC) Incidence rate per 100 patient-years in Cohort 2a (VKA) NOAC vs. VKA CO **** ( ) CO **** ( ) CO **** ( ) Incidence rate per 100 patient-years in Cohort 1 (NOAC) Incidence rate per 100 patient-years in Cohort 2 (VKA) NOAC vs. VKA **** ( ) **** ( ) **** ( ) Observed patients per group (Cohort 1/2) Observed patient-years Cohort 1 (NOAC) Observed patient-years - Cohort 2 (VKA) 6,166 37,439 5,799 25,734 5,227 19,023 * p < 0.050; ** p < 0.010; *** p < 0.005; ****p < CI: confidence interval 95%; %; CO1: effectiveness composite outcome 1; CO2: safety composite outcome 2; CO3: general composite outcome 3; IRR: Incidence rate ratio; NOAC: non-vitamin K antagonist oral anticoagulants; PSM: Propensity score matching; VKA: vitamin-k-antagonist 6
7 Supplemental Figures: Figure S1a: Results of the multivariable Cox Regression analysis addressing composite outcome 3, based on Cohorts 1 and 2 Figure Legend: Please note that all independent variables included in the regression estimates were based on the 12 months before index date, except the variable documented cancer diagnosis in observational period 7
8 Figure S1b: Results of the multivariable Cox Regression analysis addressing composite outcome 1 (effectiveness), based on Cohorts 1 and 2 Figure Legend: Please note that all independent variables included in the regression estimates were based on the 12 months before index date, except the variable documented cancer diagnosis in observational period 8
9 Figure S1c: Results of the multivariable Cox Regression analysis addressing composite outcome 2 (safety), based on Cohorts 1 and 2 Figure Legend: Please note that all independent variables included in the regression estimates were based on the 12 months before index date, except the variable documented cancer diagnosis in observational period. 9
Condition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationSupplementary Online Content
Supplementary Online Content Lin Y-S, Chen Y-L, Chen T-H, et al. Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA 2 DS 2 -VASc Score. JAMA Netw
More informationischemic stroke, transient ischemic attack, or peripheral artery embolism
Appendix Table S1: ICD- 8/1 codes and ATC- codes Population Acute myocardial infarction Defined from primary inpatient diagnoses codes PCI Defined from procedure codes Non- valvular atrial fibrillation
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationSupplementary Online Content
Supplementary Online Content Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GYH. Assessment of the CHA 2 DS 2 -VASc score in predicting ischemic stroke, thromboembolism, and death
More informationStudy period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL 1 Supplemental Table 1. ICD codes Diagnoses, surgical procedures, and pharmacotherapy used for defining the study population, comorbidity, and outcomes Study population Atrial fibrillation
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationSupplementary Online Content
Supplementary Online Content Steinhubl SR, Waalen J, Edwards AM, et al. Effect of a home-based wearable continuous electrocardiographic monitoring patch on detection of undiagnosed atrial fibrillation
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNew Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 12 th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationOn behalf of the RE-CIRCUIT Investigators. March 19, :45 am 10:55 am. Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Safety and Efficacy of Uninterrupted Anticoagulation with Dabigatran Etexilate versus in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study Hugh Calkins, M.D., 1 Stephan
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationL. Fauchier (1), S. Taillandier (1), I. Lagrenade (1), C. Pellegrin (1), L. Gorin (1), A. Bernard (1), B. Rauzy (1), D. Babuty (1), GYL.
Prognosis in patients with atrial fibrillation and CHA 2 DS 2 VASc score=0 in a real world community based cohort study: Loire Valley Atrial Fibrillation project L. Fauchier (1), S. Taillandier (1), I.
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationAnticoagulation, atrial fibrillation in elderly patients with chronic kidney disease
Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease Zbigniew Heleniak M.D. Ph.D. Department of Nephrology, Transplantology and Internal Medicine Medical University of Gdansk
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationOn behalf of the RE-CIRCUIT Investigators. March 19, :45 am 10:55 am. Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Safety and Efficacy of Uninterrupted Anticoagulation with Dabigatran Etexilate versus Warfarin in Patients Undergoing Catheter Ablation of Atrial Fibrillation: The RE-CIRCUIT Study Hugh Calkins, M.D.,
More informationpat hways Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16
pat hways Anticoagulants, including non-vitamin K antagonist oral anticoagulants (NOACs) Key therapeutic topic Published: 26 February 2016 nice.org.uk/guidance/ktt16 Options for local implementation NICE
More informationCurrent state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice GREGORY Y H LIP MD FRCP (Lond Edin Glasg] FACC FESC Professor
More informationTRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital
TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation
More informationTemporal trends of time in therapeutic range and cardiovascular outcomes in atrial fibrillation patients.
Temporal trends of time in therapeutic range and cardiovascular outcomes in atrial fibrillation patients. Daniele Pastori(1,2), Alessio Farcomeni, Mirella Saliola, Pasquale Pignatelli, Francesco Violi*,
More informationJacqueline C. Barrientos, Nicole Meyer, Xue Song, Kanti R. Rai ASH Annual Meeting Abstracts 2015:3301
Characterization of atrial fibrillation and bleeding risk factors in patients with CLL: A population-based retrospective cohort study of administrative medical claims data in the U.S. Jacqueline C. Barrientos,
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationFølgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved
. Følgende dias er fremlagt ved DCS / DTS Fællesmøde 13. januar 2011 og alle rettigheder tilhører foredragsholderen. Gengivelse må kun foretages ved tilladelse Antithrombotic therapy in Atrial Fibrillation
More informationNOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB
NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Svanström H, Pasternak B, Hviid A. Use of azithromycin and
More informationSupplementary Table S1: Proportion of missing values presents in the original dataset
Supplementary Table S1: Proportion of missing values presents in the original dataset Variable Included (%) Missing (%) Age 89067 (100.0) 0 (0.0) Gender 89067 (100.0) 0 (0.0) Smoking status 80706 (90.6)
More informationThrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE
Thrombolysis-WAKE UP Intra-arterial interventions DEFUSE 3 Haemorrhagic Stroke - TICH 2 Secondary Prevention CROMIS 2 Secondary Prevention NAVIGATE ESUS Progression of haematoma Anticoagulation Large ICH
More informationNew Study Presented at American Heart Association (AHA) Scientific Sessions 2016:
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com New Study Presented at American Heart Association (AHA) Scientific Sessions
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationEffectiveness and Safety of Non Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation
Effectiveness and Safety of Non Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation 3 2018 Stefan H. Hohnloser; Edin Basic; Christopher Hohmann;
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation Nielsen, Peter Brønnum; Skjøth, Flemming; Rasmussen, Lars Hvilsted; Larsen, Torben Bjerregaard; Lip, Gregory DOI: 10.1016/j.cjca.2015.01.034
More informationInvasive and Medical Treatments for Atrial Fibrillation. Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic
Invasive and Medical Treatments for Thomas J Dresing, MD Section of Electrophysiology and Pacing Cleveland Clinic Disclosures Fellow s advisory panel for St Jude Medical Speaking honoraria from: Boston
More informationA common clinical dilemma. Ischaemic stroke or TIA with atrial fibrillation MRI scan with blood-sensitive imaging shows cerebral microbleeds
Cerebral microbleeds and intracranial haemorrhage risk in patients with atrial fibrillation after acute ischaemic stroke or transient ischaemic attack: multicentre observational cohort study D. Wilson,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationAF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China
AF in Asian: which NOAC to choose for particular patient and at what dose? DEJIA HUANG West China Hospital of Sichuan University, Chengdu, China Case report 64-year-old Chinese man with history of hypertension,
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAnticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet?
Anticoagulatie en de oudere patiënt: Terughoudenheid gerechtvaardigd of niet? 16/06/2018 apr. Julie Hias Satellite symposium supported by the Alliance BMS/Pfizer 432BE18PR03459/ 180570 (Date of Preparation:
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada Inc.) New Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation:
More informationInvestor Conference Call
Investor Conference Call Data from the Phase III COMPASS trial, A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationUse of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program
Use of Propensity Scores to Assess Comparability of Treatment Groups in a Registry Program Kenneth J Rothman On behalf of Menno V Huisman, Gregory Y.H. Lip, Hans-Christoph Diener, Sergio J Dubner, Chang-Sheng
More informationRESEARCH. Shirley V Wang, Jessica M Franklin, Robert J Glynn, Sebastian Schneeweiss, Wesley Eddings, Joshua J Gagne. open access
open access Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study Shirley V Wang, Jessica M Franklin,
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationSupplementary Online Content
Supplementary Online Content Pincus D, Ravi B, Wasserstein D. Association between wait time and 30-day mortality in adults undergoing hip fracture surgery. JAMA. doi: 10.1001/jama.2017.17606 eappendix
More informationCADTH Therapeutic Review
Canadian Agency for Drugs and Technologies in Health Agence canadienne des médicaments et des technologies de la santé CADTH Therapeutic Review August 2012 Volume 1, Issue 1A Antithrombotic Therapy for
More informationSupplementary Online Content
Supplementary Online Content Lee C-C, Lee M-tG, Chen Y-S. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Medicine. Published online October 5, 2015.
More informationAF stroke prevention in the Canadian context
AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network
More informationFigure 1. Number of spontaneous reports received by Lareb for the NOACs per year for different sources
1.1. Overview of reports on novel oral anticoagulants (NOACs) Introduction Lareb published overviews of reports concerning the novel anticoagulants (NOACs) apixaban (Eliquis ), dabigatran (Pradaxa ) and
More informationHypertension and Atrial Fibrillation in 2017
Boma Inn, Eldoret, 24th 25thFebruary 2017 Hypertension and Atrial Fibrillation in 2017 Dr Mzee Ngunga Consultant Cardiologist Aga Khan University Hospital, Nairobi Objectives 1. Understand the relationship
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More informationAntithrombotic therapy in CAD patients with concomitant NAFV: why and for whom?
Antithrombotic therapy in CAD patients with concomitant NAFV: why and for whom? Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Patients (%) Patients
More information'VENICE'ARRYTHMIAS'2015'' Venice,'17 th 'October'2015''
'VENICE'ARRYTHMIAS'2015'' Venice,'17 th 'October'2015'' COST-EFFECTIVENESS OF DABIGATRAN EXILATE IN TREATMENT OF ATRIAL FIBRILLATION Giovanni'Galvani,'MSc'-'Investment'Analyst'at'SC'Löwy,'London' Dr.'Giampaolo'Zoffoli'-'MD'at'Ospedale'dell
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More information